Clinical trial
Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent…
NCT00046254 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00046254 |
|---|---|
| Title | Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoporosis, Hip Fracture |
| Intervention type | Drug |
| Interventions | Zoledronic Acid |
| Enrollment | 2,127 |
| Start date | Feb 1, 2002 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Sep 25, 2002 |
| Last update posted | May 2, 2012 |
| Countries | Germany, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: